Pfizer Inc

NYSE: PFE
$26.88
-$0.59 (-2.1%)
Real Time Data Delayed 15 Min.

PFE Articles

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Apple and 3M weighed on the DJIA Wednesday while McDonald's and Pfizer gave the index a boost.
United Technologies, Pfizer, Merck, and Boeing were the stalwarts among the DJIA index stocks on Thursday.
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Pfizer, Goldman Sachs, JPMorgan Chase, and Caterpillar helped boost the DJIA to another gain Tuesday.
DuPont, General Electric, Pfizer, and UnitedHealth were the leading DJIA gainers Thursday.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
Nike, Cisco Systems, Home Depot, and Pfizer put the most downward pressure on the DJIA Friday.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
A few analysts released reports this past week calling for these three Dow stocks to rise even higher (at least 10%).
The DJIA was headed for a nearly flat close Thursday, with Pfizer and UnitedHealth offsetting share price declines at Apple and DuPont.
A few analysts released reports Wednesday calling for three Dow stocks to rise even higher. It seems at this rate that 23,000 is just around the corner.
The top analyst upgrades, downgrades and other research calls from Wednesday include Apple, Caterpillar, Pfizer, Royal Caribbean, Shopify, Under Armour and Walmart.
Pharmaceuticals maker Pfizer reported second-quarter earnings before markets opened Tuesday, beating profit estimates by a penny a share, but coming up short on revenues.